Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assays.

ABSTRACT:

Introduction

Blinatumomab (BLN) is a bispecific T-cell engager that has revolutionized the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), significantly improving outcomes in both adults and children. By simultaneously binding to CD19 on B cells and CD3 on T cells, BLN triggers target cell-dependent T-cell activation, resulting in the cytolysis of CD19⁺ BCP-ALL cells. Despite the remarkable clinical advancements achieved with BLN, the immunological mechanisms underlying treatment response or failure remain poorly characterized. γδ T cells are attractive candidates for adoptive T-cell therapy due to potent cytotoxicity, capacity to present antigens, broad lysis of different tumor entities, and low alloreactivity. Because γδ T cells can also be redire

SUBMITTER: Kelm M 

PROVIDER: S-EPMC12920462 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature